Clinical Trials - February 16, 2022
Elypta launches Multi-Cancer Early Detection screening study
Elypta has announced the launch of a clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study, LEVANTIS-0087A (LEV87A), aims to detect any-type cancer in adults who show no symptoms or have any recent history of cancer. […]
New Market - February 4, 2021
Elypta launches research service for glycosaminoglycan profiling
Elypta has announced the launch of the first standardized service for full spectrum glycosaminoglycan quantification for researchers. Elypta is also launching a sponsorship program to support more academic research in the field, prioritizing fundamental, pre-clinical, and clinical questions about how glycosaminoglycans relate to cancer. Glycosaminoglycan profiling Glycosaminoglycans (GAGs) are polysaccharides with relevance across a wide […]
Intellectual Property - January 29, 2021
Elypta granted US patent
The molecular diagnostics firm Elypta announced that it has been granted a patent by the United States Patent and Trademark Office for its novel liquid biopsy method for cancer diagnostics. The patent concerns a method for screening for renal cell carcinoma, the most common form of kidney cancer, by measuring specific metabolites – glycosaminoglycans (GAGs) […]
Clinical Trials - February 11, 2020
First patient enrolled in Elypta trial
Elypta has enrolled the first patient in the multi-center AURORAX-087A (AUR87A) study involving its novel liquid biopsy platform. This was achieved at the department of Urology, Norfolk and Norwich University Hospital, UK. Involving 16 hospitals across the EU and US, AUR87A is the largest ever prospective multi-center diagnostic test study for the detection of recurrence […]
Financing - January 23, 2020
Elypta raises €6 million
Elypta has raised €6.1 million in a late seed funding round closing in December 2019 and led by Industrifonden and Sciety. Norrsken Foundation’s newly raised impact fund also contributed, marking the first time the three entities have invested together. Other investors included Barcelona-based seed fund Nina Capital and Chalmers Ventures who has been an owner […]
MedTech Award - August 16, 2019
Swedish companies nominated for “Medtech Oscars”
Elypta, Pilloxa and Sigrid Therapeutics have been announced as finalists in this year’s Medtech Insight Awards, an award that celebrates and recognizes excellence among the companies, teams, and individuals driving positive change across the global medtech industry. Ten distinct categories cover notable achievements across the device and diagnostics industries, from technological innovations and partnerships, to […]
